Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15628295 | 0.89 | TNKS (0.40) | TNKSKDM1AMAOAMAOBRCOR1 | |
| SCHEMBL1377738 | 0.82 | KDM1A (0.46) | TNKSKDM1AMAOAMAOBRCOR1 | |
| SCHEMBL13167913 | 0.81 | HSD11B1 (0.47) | TNKSKDM1AMAOAMAOBRCOR1 | |
| SCHEMBL6099462 | 0.81 | TNKS (0.45) | TNKSKDM1AMAOAMAOBRCOR1 | |
| SCHEMBL2646792 | 0.81 | KDM1A (0.45) | TNKSKDM1AMAOAMAOBRCOR1 | |
| SCHEMBL2535607 | 0.81 | TNKS (0.45) | TNKSKDM1AMAOAMAOBRCOR1 | |
| SCHEMBL2535612 | 0.81 | DGAT1 (0.51) | TNKSKDM1AMAOAMAOBRCOR1 | |
| SCHEMBL1455890 | 0.81 | BCL2 (0.48) | TNKSKDM1AMAOAMAOBRCOR1 | |
| SCHEMBL27288400 | 0.80 | TNKS (0.42) | TNKSKDM1AMAOAMAOBRCOR1 | |
| SCHEMBL297319 | 0.80 | MEN1 (0.54) | TNKSKDM1AFAAHBCL2BECN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | TNKS 1500/4885KDM1A 1021/4885MAOA 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.